Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Endocrinology|March 16, 2012
Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiencyAlberto Falorni, Annalisa Brozzetti, Maria Chiara Aglietti, et al.
The Journal of Clinical Endocrinology and Metabolism|March 4, 2015
Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's diseaseAnnalisa Brozzetti, Mohammad Alimohammadi, Silvia Morelli, et al.
Endocrine|March 23, 2016
Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathyMariacarla Moleti, Giuseppe Giuffrida, Giacomo Sturniolo, et al.
Frontiers in Plant Science|June 24, 2024
GranoScan: an AI-powered mobile app for in-field identification of biotic threats of wheatRiccardo Dainelli, Antonio Bruno, Massimo Martinelli, et al.
The Journal of Clinical Endocrinology and Metabolism|March 19, 2019
Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-LikeRiccardo Giannini, Sonia Moretti, Clara Ugolini, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2024
Wnt/B-catenin Activation and TP53 Mutations Associate With Distinct Immune Profiles in Advanced Thyroid CancerSonia Moretti, Martina Mandarano, Elisa Menicali, et al.
The Journal of Biological Chemistry|December 21, 2016
Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1Sonia Moretti, Elisa Menicali, Nicole Nucci, et al.
European Journal of Endocrinology|May 26, 2010
Autoantibody responses in autoimmune ovarian insufficiency and in Addison's disease are IgG1 dominated and suggest a predominant, but not exclusive, Th1 type of responseAnnalisa Brozzetti, Stefania Marzotti, Daria La Torre, et al.
European Thyroid Journal|April 13, 2026
Real-world efficacy of Lenvatinib/Pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centersEdoardo Talpacci, Manuela Macera, Giulia Maida, et al.
The Journal of Clinical Endocrinology and Metabolism|February 13, 2014
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironmentSonia Moretti, Elisa Menicali, Pasquale Voce, et al.
Pageof 3